2021
DOI: 10.1038/s41416-021-01536-1
|View full text |Cite
|
Sign up to set email alerts
|

NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

5
18
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 25 publications
(23 citation statements)
references
References 44 publications
5
18
0
Order By: Relevance
“…A recent study also supports the detection of NTRK fusions across nine cancer types [32]. In this study, the authors report a PPV of 88% (CI 51-98%), which is similar to that observed here.…”
Section: Discussionsupporting
confidence: 91%
“…A recent study also supports the detection of NTRK fusions across nine cancer types [32]. In this study, the authors report a PPV of 88% (CI 51-98%), which is similar to that observed here.…”
Section: Discussionsupporting
confidence: 91%
“…NTRK gene fusions are emerging biomarkers and their use in translational research and also for patients’ stratification is at its beginning. Particularly, NTRK1-3 fusions with other genes were recently studied in several solid tumors harboring this signature as predictors of prognosis ( Table 2 ) [ [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] ]. In thyroid carcinomas, a cohort of 259 patients assessed NTRK chromosomal rearrangements and their correlation with histological patterns [ 39 ].…”
Section: Ntrk Fusions As Prognostic Biomarkersmentioning
confidence: 99%
“…However, other recent reports found that these alterations may be associated with acquired resistance to tyrosine kinase inhibitors and also with unfavorable survival outcomes, respectively, in non-small cell lung cancer and other multiple solid cancers [ 40 , 44 ]. Promisingly and in a recent advance, Rolfo et al investigated a liquid biopsy-based approach to assess activating fusions of NTRK in circulating tumor DNA (ctDNA) from patients with advanced solid cancers [ 38 ]. These authors were able to identify NTRK1 fusions including some unique alterations that were correlated with those detected in corresponding tissues.…”
Section: Ntrk Fusions As Prognostic Biomarkersmentioning
confidence: 99%
See 1 more Smart Citation
“…In the NILE study, assay improvements allowed ALK fusions to be detected with increased sensitivity and 100% PPV [ 12 ]. A recent analysis exploring the potential to detect NTRK-fusions in plasma, which have several tumor-agnostic FDA drug approvals, has also shown to be feasible with high PPV [ 97 ].…”
Section: Limitations Of Plasma Ctdna Testing In Clinical Practicementioning
confidence: 99%